# Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

> **NCT00203892** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Chicago** · enrollment: 23 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **BIOLOGICAL:** modified CEA peptide (10mcg)
- **BIOLOGICAL:** modified CEA peptide (100mcg)
- **BIOLOGICAL:** modified CEA peptide (1000mcg)

## Key facts

- **NCT ID:** NCT00203892
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2009-06
- **Final completion:** 2012-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203892, "Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00203892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*